PLBIO(000403) 国投证券·2025-04-26 06:02Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 24.42 CNY, compared to the current stock price of 21.64 CNY [4]. Core Views - The company achieved a revenue of 2.655 billion CNY in 2024, representing a year-on-year growth of 14.00%. The net profit attributable to shareholders was 745 million CNY, up 21.76% year-on-year [1]. - In Q4 2024, the company reported a revenue of 764 million CNY, a decline of 19.86% year-on-year, and a net profit of 203 million CNY, down 29.14% year-on-year [1]. - The company is expanding its production capacity, with the annual capacity of the Picefiko project increasing to 1,600 tons and the Guangdong Shuanglin project expected to reach 1,500 tons by mid-2025, ensuring long-term sustainable development [2][3]. Summary by Sections Financial Performance - In 2024, the company achieved a net profit margin of 28.07%, an increase of 1.81 percentage points year-on-year, and a period expense ratio of 16.70%, a decrease of 4.26 percentage points year-on-year [1]. - For Q1 2025, the company reported a revenue of 375 million CNY, a decrease of 14.00% year-on-year, and a net profit of 89 million CNY, down 26.95% year-on-year [2]. Plasma Collection and Expansion - The company adopted a dual strategy of internal growth and external expansion in plasma collection, achieving over 1,400 tons of plasma collection in 2024, which supports product supply and rapid growth in annual operating performance [3]. - The company has completed the acceptance of new plasma stations and is expanding the number of plasma donors to increase collection rates [3]. Product Development - The company has over 10 products in advanced stages of research and development, with significant progress in clinical trials for several key products, enhancing market competitiveness [4]. - The comprehensive utilization rate of plasma is expected to continue increasing with the launch of new products [9]. Future Projections - Revenue growth is projected at 16.2%, 13.9%, and 12.2% for 2025 to 2027, respectively, with net profit growth of 19.8%, 16.5%, and 14.2% during the same period [9].